[1. Cleveland E, Bandy A and VanWagner LB. Diagnostic Challenges Of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2018; 11(4) 98-104. DOI:10.1002/cld.716.10.1002/cld.716610363530147867]Open DOISearch in Google Scholar
[2. Younossi ZM. The Epidemiology Of Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2018; 11(4):92-94. DOI:10.1002/cld.710.10.1002/cld.710638594730992797]Open DOISearch in Google Scholar
[3. Naim A, Scott A. An Update On The Pharmacological Treatment Of Nonalcoholic Fatty Liver Disease: Beyond Lifestyle Modifications. Clinical Liver Disease, 2018; 11(4):82-86. DOI:10.1002/cld.708.10.1002/cld.708637031630761212]Open DOISearch in Google Scholar
[4. Fedchuk L, Nascimbeni F, Pais R, et al. Performance And Limitations Of Steatosis Biomarkers In Patients With Nonalcoholic Fatty Liver Disease. Alimentary Pharmacology & Therapeutics, 2014; 40(10):1209-1222. DOI:10.1111/apt.12963.10.1111/apt.1296325267215]Search in Google Scholar
[5. Lonardo A, Nascimbeni F, Maurantonio M, et al. Nonalcoholic Fatty Liver Disease: Evolving Paradigms. World Journal Of Gastroenterology, 2017; 23(36):6571-6592. DOI:10.3748/wjg.v23.i36.6571.10.3748/wjg.v23.i36.6571564328229085206]Open DOISearch in Google Scholar
[6. Kitade H, Chen G, Ni Y and Ota T. Nonalcoholic Fatty Liver Disease And Insulin Resistance: New Insights And Potential New Treatments. Nutrients, 2017; 9(4):387. DOI:10.3390/nu9040387.10.3390/nu9040387540972628420094]Open DOISearch in Google Scholar
[7. Fruci B, Giuliano S, Mazza A, et al. Nonalcoholic Fatty Liver: A Possible New Target For Type 2 Diabetes Prevention And Treatment. International Journal Of Molecular Sciences, 2013; 14(11):22933-22966. DOI:10.3390/ijms141122933.10.3390/ijms141122933385609924264040]Open DOISearch in Google Scholar
[8. Franch-Nadal J, Caballeria L, Mata-Cases M, et al. Fatty Liver Index Is A Predictor Of Incident Diabetes In Patients With Prediabetes: The PREDAPS Study. PLOS ONE, 2018; 13(6):e0198327. DOI:10.1371/journal.pone.0198327.10.1371/journal.pone.0198327598353329856820]Search in Google Scholar
[9. Wallace T, Levy J and Matthews D. Use and Abuse of HOMA Modeling. Diabetes Care, 2004; 27(6):1487-1495. DOI: 10.2337/diacare.27.6.148710.2337/diacare.27.6.148715161807]Open DOISearch in Google Scholar
[10. “Fatty Liver Index - Mdcalc”. Mdcalc.Com, Available from: https://www.mdcalc.com/fatty-liver-index (accessed at 28 December 2018)]Search in Google Scholar
[11. “Hepatic Steatosis Index (HSI) Calculator”. Available from: https://www.mdapp.co/hepatic-steatosis-index-hsi-calculator-357/ (accessed at 28 December 2018)]Search in Google Scholar
[12. “Non-Alcoholic Fatty Liver Disease - Liver Fat Score (NAFLD-LFS) Calculator”. Available from:https://www.mdapp.co/non-alcoholic-fatty-liver-disease-liver-fat-score-nafld-lfs-calculator-358/ (accessed at 28 December 2018)]Search in Google Scholar
[13. Grigorescu ED, Mihai BM, Lăcătușu CM et al. Relationships between insulin resistance, subclinical inflammation and diastolic dysfunction in type 2 diabetes. Paper presented at the 44th National Congress of the Romanian Society of Diabetes, Nutrition and Metabolic Diseases. 23-26 May 2018, Poiana Brasov, Romania]Search in Google Scholar
[14. Gábor Firneisz. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: The liver disease of our age? World J Gastroenterol, 2014; 20(27):9072–9089. DOI: 10.3748/wjg.v20.i27.907210.3748/wjg.v20.i27.9072411287825083080]Open DOISearch in Google Scholar
[15. Bril F and Kenneth C. Management Of Nonalcoholic Fatty Liver Disease In Patients With Type 2 Diabetes: A Call To Action. Diabetes Care, 2017; 40(3):419-430. DOI:10.2337/dc16-1787.10.2337/dc16-178728223446]Open DOISearch in Google Scholar
[16. Ormazabal V, Nair S, Elfeky O et al. Association between insulin resistance and the development of cardiovsacular disease. Cardiovasc Diabetol, 2018:17-122, DOI: 10.1186/s12933-018-0762-410.1186/s12933-018-0762-4611924230170598]Open DOISearch in Google Scholar
[17. Frati G, Schirone L, Chimenti I et al. An overview of the inflammatory signalling mechanism in the myocardium underlying the development of diabetic cardiomyopathy. Cardiovascular Research, 2017; 113:378-388.10.1093/cvr/cvx01128395009]Search in Google Scholar
[18. Nishida K, Otsu K. Inflammation and metabolic cardiomyopathy. Cardiovascular Research, 2017;113:389–398. DOI:10.1093/cvr/cvx01210.1093/cvr/cvx01228395010]Open DOISearch in Google Scholar
[19. Grigorescu ED, Șorodoc V, Floria M. The Inflammatory Marker hsCRP as a Predictor of Increased Insulin Resistance in Type 2 Diabetics without Atherosclerotic Manifestations. REV.CHIM.(Bucharest), 2019; 70(5):1791-1794.10.37358/RC.19.5.7216]Search in Google Scholar
[20. Elimam H, Abdulla AM and Taha IM. Inflammatory Markers And Control Of Type 2 Diabetes Mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2019; 13(1): 800-804. DOI:10.1016/j.dsx.2018.11.061.10.1016/j.dsx.2018.11.06130641811]Open DOISearch in Google Scholar
[21. Mantovani A, Pernigo M, Bergamini C, et al. Heart Valve Calcification In Patients With Type 2 Diabetes And Nonalcoholic Fatty Liver Disease. Metabolism, 2015; 64(8):879-887. DOI:10.1016/j.metabol.2015.04.003.10.1016/j.metabol.2015.04.00325957758]Search in Google Scholar
[22. Bonapace S, Perseghin G, Molon G, et al. Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction In Patients With Type 2 Diabetes. Diabetes Care, 2011; 35 (2): 389-395. DOI:10.2337/dc11-1820.10.2337/dc11-1820326388422210573]Open DOISearch in Google Scholar
[23. Tokita Y, Maejima Y, Shimomura, et al. Non-Alcoholic Fatty Liver Disease Is A Risk Factor For Type 2 Diabetes In Middle-Aged Japanese Men And Women. Internal Medicine, 2017; 56(7): 763-771. DOI:10.2169/internalmedicine.56.7115.10.2169/internalmedicine.56.7115545791828381741]Open DOISearch in Google Scholar
[24. Leoni S, Tovoli F, Napoli L, et al. Current Guidelines For The Management Of Non-Alcoholic Fatty Liver Disease: A Systematic Review With Comparative Analysis. World Journal Of Gastroenterology, 2018; 24(30):3361-3373. DOI:10.3748/wjg.v24.i30.336110.3748/wjg.v24.i30.3361609258030122876]Open DOISearch in Google Scholar
[25. Kahl S, Straßburger K, Nowotny B, et al. Comparison Of Liver Fat Indices For The Diagnosis Of Hepatic Steatosis And Insulin Resistance. Plos ONE, 2014; 9(4):e94059. DOI:10.1371/journal.pone.0094059.10.1371/journal.pone.0094059398606924732091]Search in Google Scholar
[26. Yadav D, Choi E, Ahn SV, et al. Fatty Liver Index As A Simple Predictor Of Incident Diabetes From The Koges-ARIRANG Study. Medicine, 2016; 95(31):e4447. DOI:10.1097/md.0000000000004447.10.1097/MD.0000000000004447497982727495073]Open DOISearch in Google Scholar
[27. Sviklāne L, Olmane E, Dzērve Z, et al. Fatty Liver Index And Hepatic Steatosis Index For Prediction Of Non-Alcoholic Fatty Liver Disease In Type 1 Diabetes. Journal Of Gastroenterology And Hepatology, 2017; 33(1):270-276. DOI:10.1111/jgh.13814.10.1111/jgh.1381428464337]Open DOISearch in Google Scholar
[28. Leite NC. Non-Alcoholic Fatty Liver Disease And Diabetes: From Physiopathological Interplay To Diagnosis And Treatment. World Journal Of Gastroenterology, 2014; 20(26): 8377. DOI:10.3748/wjg.v20.i26.8377.10.3748/wjg.v20.i26.8377409369125024596]Open DOISearch in Google Scholar
[29. Marjot T, Sbardella E, Moola A, et al. Prevalence And Severity Of Non-Alcoholic Fatty Liver Disease Are Underestimated In Clinical Practice: Impact Of A Dedicated Screening Approach At A Large University Teaching Hospital. Diabetic Medicine, 2017; 35(1):89-98. DOI:10.1111/dme.13540.10.1111/dme.1354029094442]Open DOISearch in Google Scholar
[30. Byrne CD and Giovanni T. EASL–EASD–EASO Clinical Practice Guidelines For The Management Of Non-Alcoholic Fatty Liver Disease: Is Universal Screening Appropriate?. Diabetologia, 2016; 59(6):1141-1144. DOI:10.1007/s00125-016-3910-y.10.1007/s00125-016-3910-y27053232]Open DOISearch in Google Scholar